Indivior Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Indivior Pharmaceuticals, Inc. (INDV) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $255.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- Indivior Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $255.00M, a 650.00% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $34.00M, a 466.67% increase from fiscal 2023.
- Indivior Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $6.00M.
- Indivior Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$171.00M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | $255.00M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $34.00M 10-K · filed 2026-02-26 | $28.00M 10-K · filed 2025-03-03 |
| 2023-12-31 | $6.00M 10-K · filed 2026-02-26 | $2.00M 10-K · filed 2025-03-03 |
| 2022-12-31 | -$171.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |